<DOC>
	<DOCNO>NCT00847639</DOCNO>
	<brief_summary>This multi-institution , non-randomized , open label , Phase IIa prospective trial evaluate safety tolerability maintenance lenalidomide allogeneic hematopoietic stem cell transplantation ( HCT ) . Lenalidomide maintenance therapy start day 60 90 allogeneic HCT start dose 10mg PO daily . Dose escalation de-escalation perform depend tolerability lenalidomide . Dose range 5mg every day 5 - 25 mg give daily day 1-21 28-day cycle 12 cycle maximum maximum 12 month first dose study drug . Patients follow 28 day complete 12th planned cycle lenalidomide maintenance 12 month first dose study drug , ever come first , ( 14 15 month receive allograft ) discontinuation study drug .</brief_summary>
	<brief_title>Safety Study Lenalidomide Maintenance Therapy Post Allogeneic HCT High-risk Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>One prior allograft 8/8 7/8 allele match related unrelated donor , receive 60 90 day prior initiation lenalidomide Meet diagnostic criterion symptomatic myeloma anytime prior allogeneic HCT Have highrisk multiple myeloma Received ≤ three ( 3 ) prior line therapy . Prior therapy may include : combination chemotherapy , monotherapy , lenalidomide autologous HCT . Localized radiation therapy count single line therapy . Previous progression lenalidomide exclude participation study . Received reduce intensity conditioning regimen Received receive GVHD prophylaxis regimen calcineurin inhibitor combination either methotrexate , mycophenolate mofetil ( MMF ) sirolimus Karnofsky performance score ≥ 80 ECOG ≤ 2 There must least 50 % donor chimerism evidence fall donor chimerism within 1 month enrollment Laboratory test result within range , within 14 day prior initiation lenalidomide All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® . Disease progression time study entry Patients grade IIIIV GVHD time study entry Patients require additional immunosuppressive therapy control acute GVHD corticosteroid immunosuppressive agent use prophylaxis . Concomitant use investigational agent Patients receive donor lymphocyte infusion Active CNS malignancy Uncontrolled bacterial , viral , fungal infection Prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ &lt; 5 year study entry . Known hypersensitivity desquamate rash either thalidomide lenalidomide . Known positive HIV active infectious hepatitis . Women pregnant breastfeeding . New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Allogeneic Hematopoietic Cell Transplantation</keyword>
</DOC>